<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum></forum>
<forum_title></forum_title>
<discussion_title>Pfizer Is Near $14 Billion Deal For Medivation : investors</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://peekerhealth.com/2016/08/22/pfizer-is-near-14-billion-deal-for-medivation-investors/</topic_url>
<topic_text>
Pfizer Is Near $14 Billion Deal For Medivation : investors admin_health / 22 Aug, 16 / 41 / 0 
As it stated in investors Pfizer Is Near $14 Billion Deal For Medivation 
Pfizer Is Near $14 Billion Deal For Medivation 
Pfizer (PFE) is near a deal to buy Medivation (MDVN) for about $14 billion, following months of takeover speculation for the biotech.Big Pharma could announce a takeover deal for Medivation as soon as Monday, according to multiple reports.Medivation closed Friday at 67.16, with a market valuation of $11.1 billion. 
coupled with ibtimes Pfizer (PFE) Nears Medivation Acquisition In $14 Billion Cash Deal 
Pfizer (PFE) Nears Medivation Acquisition In $14 Billion Cash Deal 
Less than four months after Medivation Inc. turned down a $9.3 billion takeover offer from French pharmaceutical heavyweight Sanofi SA, the company has reportedly reached an agreement with Pfizer Inc., the world’s second-largest drugmaker, to be bought for about $14 billion.The deal is expected to be announced as soon as Monday.Many big names in the pharma space have been eyeing the San Francisco biotechnology company for its cancer drugs, particularly for Xtandi, which is used in the treatment for prostate cancer. 
moreover from bloomberg Pfizer Said Close to $14 Billion Deal to Acquire Medivation 
Pfizer Said Close to $14 Billion Deal to Acquire Medivation 
Pfizer Inc. is close to an agreement to buy Medivation Inc. for about $14 billion, people familiar with the situation said, the latest in a long run of blockbuster deals in the drug and biotechnology industries.The deal may be announced as early as Monday, said the people, who asked not to be identified because the matter is still private.The biotech company’s shares closed at $67.16 on Friday, giving it a market value of $11.1 billion. Post Views: 52 
</topic_text>
<spam_score>0.03</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://peekerhealth.com/2016/08/22/pfizer-is-near-14-billion-deal-for-medivation-investors/</post_url>
<post_date>20160822</post_date>
<post_time></post_time>
<username></username>
<post>
Pfizer Is Near $14 Billion Deal For Medivation : investors admin_health / 22 Aug, 16 / 41 / 0 
As it stated in investors Pfizer Is Near $14 Billion Deal For Medivation 
Pfizer Is Near $14 Billion Deal For Medivation 
Pfizer (PFE) is near a deal to buy Medivation (MDVN) for about $14 billion, following months of takeover speculation for the biotech.Big Pharma could announce a takeover deal for Medivation as soon as Monday, according to multiple reports.Medivation closed Friday at 67.16, with a market valuation of $11.1 billion. 
coupled with ibtimes Pfizer (PFE) Nears Medivation Acquisition In $14 Billion Cash Deal 
Pfizer (PFE) Nears Medivation Acquisition In $14 Billion Cash Deal 
Less than four months after Medivation Inc. turned down a $9.3 billion takeover offer from French pharmaceutical heavyweight Sanofi SA, the company has reportedly reached an agreement with Pfizer Inc., the world’s second-largest drugmaker, to be bought for about $14 billion.The deal is expected to be announced as soon as Monday.Many big names in the pharma space have been eyeing the San Francisco biotechnology company for its cancer drugs, particularly for Xtandi, which is used in the treatment for prostate cancer. 
moreover from bloomberg Pfizer Said Close to $14 Billion Deal to Acquire Medivation 
Pfizer Said Close to $14 Billion Deal to Acquire Medivation 
Pfizer Inc. is close to an agreement to buy Medivation Inc. for about $14 billion, people familiar with the situation said, the latest in a long run of blockbuster deals in the drug and biotechnology industries.The deal may be announced as early as Monday, said the people, who asked not to be identified because the matter is still private.The biotech company’s shares closed at $67.16 on Friday, giving it a market value of $11.1 billion. Post Views: 52 
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://peekerhealth.com/wp-content/uploads/picture-3122.jpg</main_image>
</document>
